Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
Topic
- Advertising (294)
- COVID-19 (164)
- Safety monitoring and information (121)
- Compliance and enforcement (101)
- Legislation (80)
- Manufacturing (60)
- Vaping hub (59)
- Labelling and packaging (46)
- Import and export (41)
- Medicinal cannabis hub (28)
- Scheduling (national classification system) (28)
- Sunscreens (21)
- Weight loss products (18)
- Shortages and supply disruptions (10)
- Committees and advisory bodies (9)
- Cosmetics (6)
- Clinical trials (5)
- Unique Device Identification (UDI) hub (5)
- Fees and payments (2)
- Prescription opioids hub (2)
- Urogynaecological (transvaginal) surgical mesh hub (2)
- Breast implant hub (1)
Search
1309 result(s) found, displaying 851 to 875
-
COVID-19 vaccine safety reportsInformation about the TGA's safety monitoring of COVID-19 vaccines.
-
Media releasesThe TGA, part of the Department of Health, has granted provisional determination to Moderna Australia Pty Ltd in relation to the COVID-19 Vaccine, Elasomeran
-
Safety updatesHealth professionals are advised that the Product Information (PI) documents for combined oral contraceptives containing dienogest have been updated to include more detailed information on the risk of venous thromboembolism.
-
Safety updatesHealth professionals are advised that the Product Information (PI) documents for sertraline have been updated to include microscopic colitis as a potential adverse effect of unknown frequency based on post-marketing experience.
-
Safety updatesThe recommended duration of contraception after finishing tamoxifen treatment has been extended from two months to nine months.
-
COVID-19 vaccine safety reportsInformation about the TGA's safety monitoring of COVID-19 vaccines.
-
Media releasesInteraction between TGA and AHPRA advertising guidelines
-
Safety updatesConsumer goods with button batteries
-
COVID-19 vaccine safety reportsInformation about the TGA's safety monitoring of COVID-19 vaccines.
-
Media releasesThe TGA has issued two infringement notices totalling $26,640 to Sydney company Aidacare Pty Ltd (Aidacare).
-
Media releasesThe TGA is seriously concerned about misleading information that has been broadcast on radio stations providing a distorted picture of the safety of COVID-19 vaccines.
-
Media releasesThe TGA has implemented arrangements to facilitate the communication of information about approved COVID-19 vaccines.
-
COVID-19 vaccine safety reportsInformation about the TGA's safety monitoring of COVID-19 vaccines.
-
News articlesDetails of affected Aspen Medical respirator batches, including ARTG entries, manufacturers, batch numbers and expiry dates, following a TGA product defect alert on labelling.
-
Media releasesThe TGA has issued three infringement notices to a Queensland man for the alleged unlawful importation of a medicine containing Armodafinil.
-
Media releasesThe TGA has issued two infringement notices to a dentist from Western Australia for the alleged unlawful importation of cosmetic injectables.
-
Media releasesThe TGA has issued two infringement notices to Perth-based company V P & Associates Pty Ltd (V P & Associates), for alleged unlawful advertising of a medical device in relation to SARS-CoV-2 Human Coronavirus.
-
News articlesWe are improving the Medicine Shortages IT System.
-
Regulatory decision noticesDirection Notice issued to cease advertising of therapeutic goods not entered in the ARTG
-
COVID-19 vaccine safety reportsInformation about the TGA's safety monitoring of COVID-19 vaccines.
-
Media releasesThe TGA is warning sponsors not to advertise listed medicines that are not included in the ARTG with permitted indications
-
News articlesRemaking of standards and legislative instruments for human cell and tissue (HCT) products, blood and blood components
-
Media releasesPeter Evans Chef Pty Ltd fined $79,920 for alleged unlawful advertising
-
News articlesUpdated storage conditions for the Pfizer COVID-19 vaccine
-
News articlesThe TGA granted a provisional determination to GlaxoSmithKline Australia Pty Ltd in relation to the monoclonal antibody treatment, SOTROVIMAB (GSK4182136) on 14 April 2021